Scott Williams

Baseline PSMA PET-CT is prognostic for treatment failure in men with intermediate-to-high risk prostate cancer: 54 months follow-up of the proPSMA randomised trial

V Kasivisvanathan, DG Murphy, E Link, N Lawrentschuk, J O’Brien, JP Buteau, M Roberts, RJ Francis, C Tang, I Vela, P Thomas, N Rutherford, J Martin, M Frydenberg, R Shakher, L-M Wong, K Taubman, ST Lee, E Hsiao, M Nottage, et al.

Journal article  |  2023  |  European Urology

Semi-quantitative and quantitative dynamic contrast-enhanced (DCE) MRI parameters as prostate cancer imaging biomarkers for biologically targeted radiation therapy.

Hayley M Reynolds, Sirisha Tadimalla, Yu-Feng Wang, Maryam Montazerolghaem, Yu Sun, Scott Williams, Catherine Mitchell, Mary E Finnegan, Declan G Murphy, Annette Haworth

Journal article  |  2022  |  Cancer Imaging

BACKGROUND: Biologically targeted radiation therapy treatment planning requires voxel-wise characterisation of tumours. Dynamic co..

A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary

Atara Posner, Owen Wj Prall, Tharani Sivakumaran, Dariush Etemadamoghadam, Niko Thio, Andrew Pattison, Shiva Balachander, Krista Fisher, Samantha Webb, Colin Wood, Anna DeFazio, Nicholas Wilcken, Bo Gao, Christos S Karapetis, Madhu Singh, Ian M Collins, Gary Richardson, Christopher Steer, Mark Warren, Narayan Karanth, et al.

Journal article  |  2022  |  JOURNAL OF PATHOLOGY

Cancer of unknown primary (CUP) is a syndrome defined by clinical absence of a primary cancer after standardised investigations. G..

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [Lu-177]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, 2 trial

James P Buteau, Andrew J Martin, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M Joshua, Roslyn J Francis, Alison Y Zhang, Andrew M Scott, Sze-Ting Lee, Arun A Azad, Margaret M McJannett, Martin R Stockler, Scott G Williams, Ian Davis, Michael S Hofman

Journal article  |  2022  |  LANCET ONCOLOGY

BACKGROUND: Previously, results from the TheraP trial showed that treatment with lutetium-177 [177Lu]Lu-PSMA-617 improved frequenc..

Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?

Maha Hussain, Michael A Carducci, Noel Clarke, Sarah E Fenton, Karim Fizazi, Silke Gillessen, Heather Jacene, Michael J Morris, Fred Saad, Oliver Sartor, Mary-Ellen Taplin, Neha Vapiwala, Scott Williams, Christopher Sweeney

Journal article  |  2022  |  JOURNAL OF CLINICAL ONCOLOGY

Modelling aggressive prostate cancers of young men in immune-competent mice, driven by isogenic Trp53 alterations and Pten loss

Javier Octavio Mejia-Hernandez, Simon P Keam, Reem Saleh, Fenella Muntz, Stephen B Fox, David Byrne, Arielle Kogan, Lokman Pang, Jennifer Huynh, Cassandra Litchfield, Franco Caramia, Guillermina Lozano, Hua He, James M You, Shahneen Sandhu, Scott G Williams, Ygal Haupt, Sue Haupt

Journal article  |  2022  |  CELL DEATH & DISEASE

Understanding prostate cancer onset and progression in order to rationally treat this disease has been critically limited by a dir..

Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status

Javier Octavio Mejia-Hernandez, Dinesh Raghu, Franco Caramia, Nicholas Clemons, Kenji Fujihara, Thomas Riseborough, Amina Teunisse, Aart G Jochemsen, Lars Abrahmsen, Giovanni Blandino, Andrea Russo, Cristina Gamell, Stephen B Fox, Catherine Mitchell, Elena A Takano, David Byrne, Panimaya Jeffreena Miranda, Reem Saleh, Heather Thorne, Shahneen Sandhu, et al.

Journal article  |  2022  |  CANCERS

Metastatic prostate cancer is a lethal disease in patients incapable of responding to therapeutic interventions. Invasive prostate..

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.

Tamim Niazi, Sean Matthew McBride, Scott Williams, Ian D Davis, Martin R Stockler, Andrew James Martin, Karen Bracken, Felicia Roncolato, Lisa Horvath, Shomik Sengupta, Jarad Martin, Tee Lim, Simon Hughes, Raymond S McDermott, James WF Catto, Paul J Kelly, Wendy R Parulekar, Scott Carlyle Morgan, Ricardo A Rendon, Christopher Sweeney

Journal article  |  2022  |  Journal of Clinical Oncology

TPS5103 Background: Radiation therapy (RT), plus androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone ..

PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).

Shahneen Sandhu, Anthony M Joshua, Louise Emmett, Lavinia Anne Spain, Lisa Horvath, Megan Crumbaker, Angelyn Anton, Roslyn Wallace, Anupama Pasam, Mathias Bressel, Erin Cassidy, Patricia Banks, Nattakorn Dhiantravan, Timothy J Akhurst, Aravind Ravi Kumar, Ramin Alipour, Mark Scalzo, Scott Williams, Rodney Hicks, Michael S Hofman

Conference Proceedings  |  2022  |  Journal of Clinical Oncology

5017 Background: The VISION and TheraP trials have established the safety and efficacy of 177Lu-PSMA-617 in mCRPC with a 50% PSA ..

Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes

Anna Sofia Trigos, Anupama Pasam, Patricia Banks, Roslyn Wallace, Christina Guo, Simon Keam, Heather Thorne, Catherine Mitchell, Stephen Lade, David Clouston, Alexander Hakansson, Yang Liu, Benjamin Blyth, Declan Murphy, Nathan Lawrentschuk, Damien Bolton, Daniel Moon, Phil Darcy, Ygal Haupt, Scott G Williams, et al.

Journal article  |  2022  |  JOURNAL FOR IMMUNOTHERAPY OF CANCER

BACKGROUND: Aberrations in homologous recombination repair (HRR) genes are emerging as important biomarkers for personalized treat..